PMID- 38104105
OWN - NLM
STAT- MEDLINE
DCOM- 20231219
LR  - 20231219
IS  - 1471-2407 (Electronic)
IS  - 1471-2407 (Linking)
VI  - 23
IP  - 1
DP  - 2023 Dec 16
TI  - Baseline C-reactive protein predicts efficacy of the first-line immune checkpoint 
      inhibitors plus chemotherapy in advanced lung squamous cell carcinoma: a 
      retrospective, multicenter study.
PG  - 1244
LID - 10.1186/s12885-023-11737-x [doi]
LID - 1244
AB  - AIMS: To investigate the predictive value of baseline C-reactive protein (CRP) 
      levels on the efficacy of chemotherapy plus immune checkpoint inhibitors (ICI) in 
      patients with advanced lung squamous cell carcinoma (LSCC). MATERIALS AND 
      METHODS: In this retrospective multicenter study spanning from January 2016 to 
      December 2020, advanced LSCC patients initially treated with chemotherapy or a 
      combination of chemotherapy and ICI were categorized into normal and elevated CRP 
      subgroups. The relationship between CRP levels and treatment outcomes was 
      analyzed using multivariate Cox proportional hazards models and multivariate 
      logistic regression, focusing primarily on the progression-free survival (PFS) 
      endpoint, and secondarily on overall survival (OS) and objective response rate 
      (ORR) endpoints. Survival curves were generated using the Kaplan-Meier method, 
      with the log-rank test used for comparison between groups. RESULTS: Of the 245 
      patients evaluated, the 105 who received a combination of chemotherapy and ICI 
      with elevated baseline CRP levels exhibited a significant reduction in PFS 
      (median 6.5 months vs. 11.8 months, HR, 1.78; 95% CI: 1.12-2.81; p = 0.013) 
      compared to those with normal CRP levels. Elevated CRP was identified as an 
      independent risk factor for poor PFS through multivariate-adjusted analysis. 
      However, among the 140 patients receiving chemotherapy alone, baseline CRP levels 
      did not significantly influence PFS. Furthermore, within the combination therapy 
      group, there was a notable decrease in the ORR (51% vs. 71%, p = 0.035), coupled 
      with a significantly shorter OS (median 20.9 months vs. 31.5 months, HR, 2.24; 
      95% CI: 1.13-4.44; p = 0.033). CONCLUSION: In patients with advanced LSCC, 
      elevated baseline CRP levels were identified as an independent predictive factor 
      for the efficacy of combination therapy with chemotherapy and ICI, but not in 
      chemotherapy alone. This suggests that CRP may be a valuable biomarker for 
      guiding treatment strategies.
CI  - (c) 2023. The Author(s).
FAU - Zheng, Xinlong
AU  - Zheng X
AD  - Department of Thoracic Oncology, Clinical Oncology School of Fujian Medical 
      University, Fujian Cancer Hospital, Fuzhou, China.
FAU - Zhang, Longfeng
AU  - Zhang L
AD  - Department of Thoracic Oncology, Clinical Oncology School of Fujian Medical 
      University, Fujian Cancer Hospital, Fuzhou, China.
FAU - Wu, Lin
AU  - Wu L
AD  - The Second Department of Thoracic Oncology, the Affiliated Cancer Hospital of 
      Xiangya School of Medicine, Central South University/Hunan Cancer Hospital, 
      Changsha, China.
FAU - Zhao, Jun
AU  - Zhao J
AD  - Department of Thoracic Medical Oncology, Peking University Cancer Hospital and 
      Institute, Beijing, China.
FAU - Sun, Jianguo
AU  - Sun J
AD  - Cancer Institute, Xinqiao Hospital, Army Medical University, Chongqing, China.
FAU - Fang, Yong
AU  - Fang Y
AD  - Department of Medical Oncology, Sir Run Run Shaw Hospital, Zhejiang University, 
      Zhejiang, China.
FAU - Zhou, Jin
AU  - Zhou J
AD  - School of Medicine, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, 
      University of Electronic Science and Technology of China, Chengdu, Sichuan, 
      China.
FAU - Chu, Qian
AU  - Chu Q
AD  - Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong 
      University of Science and Technology, Wuhan, China.
FAU - Shen, Yihong
AU  - Shen Y
AD  - Department of Respiratory Diseases, The First Affiliated Hospital, College of 
      Medicine, Zhejiang University, Hangzhou, China.
FAU - Yang, Zhenzhou
AU  - Yang Z
AD  - Department of Cancer Center, The Second Affiliated Hospital, Chongqing Medical 
      University, Chongqing, China.
FAU - Chen, Lijin
AU  - Chen L
AD  - Department of Oncology, Affiliated Quanzhou First Hospital of Fujian Medical 
      University, Quanzhou, China.
FAU - Huang, Meijuan
AU  - Huang M
AD  - Department of Thoracic Oncology, Cancer Center and State Key Laboratory of 
      Biotherapy, West China Hospital, Sichuan University, Chengdu, China.
FAU - Lin, Xiaoyan
AU  - Lin X
AD  - Department of Oncology, Fujian Medical University Union Hospital, Fuzhou, China.
FAU - Liu, Zhenhua
AU  - Liu Z
AD  - Department of Medical Oncology, Provincial Clinical College, Fujian Medical 
      University, Fujian provincial hospital, Fuzhou, China.
FAU - Shen, Peng
AU  - Shen P
AD  - Department of Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, 
      China.
FAU - Wang, Zhijie
AU  - Wang Z
AD  - Medical Oncology Department, National Cancer Center/National Clinical Research 
      Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences, and 
      Peking Union Medical College, Beijing, China.
FAU - Wang, Xin
AU  - Wang X
AD  - Department of Oncology, Zhongshan Hospital of Xiamen University, Xiamen, China.
FAU - Wang, Huijuan
AU  - Wang H
AD  - Department of Respiratory Medicine, the Affiliated Cancer Hospital of Zhengzhou 
      University, Zhengzhou, China.
FAU - Han, Zhengbo
AU  - Han Z
AD  - Department of Oncology, Shengjing Hospital of China Medical University, Shenyang, 
      China.
FAU - Liu, Anwen
AU  - Liu A
AD  - Department of Oncology, The Second Affiliated Hospital of Nanchang University, 
      Nanchang, China.
FAU - Zhang, Hongmei
AU  - Zhang H
AD  - Department of Oncology, Xijing Hospital, Airforce Military Medical University, 
      Xian, Shanxi, China.
FAU - Ye, Feng
AU  - Ye F
AD  - Department of Medical Oncology, Cancer Hospital, The First Affiliated Hospital of 
      Xiamen University, School of Medicine, Xiamen University, Teaching Hospital of 
      Fujian Medical University, Xiamen, China.
FAU - Gao, Wen
AU  - Gao W
AD  - Department of Medical Oncology, The First Affiliated Hospital with Nanjing 
      Medical University, Nanjing, Jiangsu, China.
FAU - Wu, Fang
AU  - Wu F
AD  - Department of Oncology, The Second Xiangya Hospital, Central South University, 
      Changsha, Hunan, China.
FAU - Song, Zhengbo
AU  - Song Z
AD  - Department of Clinical Trial, Cancer Hospital of the University of Chinese 
      Academy of Sciences, Hangzhou, Zhejiang, China.
FAU - Chen, Shengchi
AU  - Chen S
AD  - Department of Oncology, Nanping First Hospital Affiliated to Fujian Medical 
      University, Nanping, China.
FAU - Zhou, Chenzhi
AU  - Zhou C
AD  - Respiratory Medicine Department, State Key Laboratory of Respiratory Disease, 
      National Clinical Research Center for Respiratory Disease, Guangzhou Institute of 
      Respiratory Health, The First Affiliated Hospital of Guangzhou Medical 
      University, Guangzhou, China.
FAU - Wang, Qian
AU  - Wang Q
AD  - Department of Respiratory Medicine, Affiliated Hospital of Nanjing University of 
      Chinese Medicine, Nanjing, Jiangsu, China.
FAU - Xu, Chunwei
AU  - Xu C
AD  - Department of Respiratory Medicine, Affiliated Jinling Hospital, Medical School 
      of Nanjing University Nanjing, Nanjing, Jiangsu, China.
FAU - Huang, Dingzhi
AU  - Huang D
AD  - Department of Thoracic Oncology, Tianjin Medical University Cancer Institute and 
      Hospital, Tianjin, China.
FAU - Zheng, Xiaobin
AU  - Zheng X
AD  - Department of Thoracic Oncology, Clinical Oncology School of Fujian Medical 
      University, Fujian Cancer Hospital, Fuzhou, China.
FAU - Miao, Qian
AU  - Miao Q
AD  - Department of Thoracic Oncology, Clinical Oncology School of Fujian Medical 
      University, Fujian Cancer Hospital, Fuzhou, China.
FAU - Jiang, Kan
AU  - Jiang K
AD  - Department of Thoracic Oncology, Clinical Oncology School of Fujian Medical 
      University, Fujian Cancer Hospital, Fuzhou, China.
FAU - Xu, Yiquan
AU  - Xu Y
AD  - Department of Thoracic Oncology, Clinical Oncology School of Fujian Medical 
      University, Fujian Cancer Hospital, Fuzhou, China.
FAU - Wu, Shiwen
AU  - Wu S
AD  - Department of Thoracic Oncology, Clinical Oncology School of Fujian Medical 
      University, Fujian Cancer Hospital, Fuzhou, China.
FAU - Wang, Haibo
AU  - Wang H
AD  - Department of Thoracic Oncology, Clinical Oncology School of Fujian Medical 
      University, Fujian Cancer Hospital, Fuzhou, China.
FAU - Zhang, Qiuyu
AU  - Zhang Q
AD  - Institute of Immunotherapy, Fujian Medical University, Fuzhou, China.
FAU - Yang, Shanshan
AU  - Yang S
AD  - Department of Thoracic Oncology, Clinical Oncology School of Fujian Medical 
      University, Fujian Cancer Hospital, Fuzhou, China.
FAU - Li, Yujing
AU  - Li Y
AD  - Department of Thoracic Oncology, Clinical Oncology School of Fujian Medical 
      University, Fujian Cancer Hospital, Fuzhou, China.
FAU - Chen, Sihui
AU  - Chen S
AD  - Department of Thoracic Oncology, Clinical Oncology School of Fujian Medical 
      University, Fujian Cancer Hospital, Fuzhou, China.
FAU - Lin, Gen
AU  - Lin G
AD  - Department of Thoracic Oncology, Clinical Oncology School of Fujian Medical 
      University, Fujian Cancer Hospital, Fuzhou, China. fjzllg133@fjzlhospital.com.
AD  - Fujian Key Laboratory of Advanced Technology for Cancer Screening and Early 
      Diagnosis, Fuzhou, China. fjzllg133@fjzlhospital.com.
AD  - Interdisciplinary Institute for Medical Engineering, Fuzhou University, Fuzhou, 
      China. fjzllg133@fjzlhospital.com.
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
DEP - 20231216
PL  - England
TA  - BMC Cancer
JT  - BMC cancer
JID - 100967800
RN  - 9007-41-4 (C-Reactive Protein)
RN  - 0 (Immune Checkpoint Inhibitors)
SB  - IM
MH  - Humans
MH  - C-Reactive Protein
MH  - Immune Checkpoint Inhibitors/pharmacology/therapeutic use
MH  - Retrospective Studies
MH  - *Carcinoma, Non-Small-Cell Lung
MH  - *Carcinoma, Squamous Cell/drug therapy
MH  - *Lung Neoplasms/drug therapy
MH  - Lung
PMC - PMC10725584
OTO - NOTNLM
OT  - C-reactive protein
OT  - Immune checkpoint inhibitors
OT  - Lung squamous cell carcinoma
OT  - Predictive biomarker
COIS- The authors declare no competing interests.
EDAT- 2023/12/17 09:45
MHDA- 2023/12/19 06:42
PMCR- 2023/12/16
CRDT- 2023/12/16 23:17
PHST- 2023/10/02 00:00 [received]
PHST- 2023/12/10 00:00 [accepted]
PHST- 2023/12/19 06:42 [medline]
PHST- 2023/12/17 09:45 [pubmed]
PHST- 2023/12/16 23:17 [entrez]
PHST- 2023/12/16 00:00 [pmc-release]
AID - 10.1186/s12885-023-11737-x [pii]
AID - 11737 [pii]
AID - 10.1186/s12885-023-11737-x [doi]
PST - epublish
SO  - BMC Cancer. 2023 Dec 16;23(1):1244. doi: 10.1186/s12885-023-11737-x.